title: Aortitis and bilateral ureteral obstruction after endovascular repair of abdominal aortic aneurysm.
abstract: A bifurcated stent graft was used to treat an asymptomatic 5.4-cm abdominal aortic aneurysm in a 76-year-old man. No endoleaks or inflammatory changes were seen on the 1-month follow-up computed tomography scan. Five months later the patient had acute renal failure and ureteral obstruction secondary to significant inflammatory changes in the aneurysm wall. After bilateral ureteral stenting, conservative treatment included tamoxifen and steroid therapy. The patient remains symptom-free, and at 2-year follow-up a computed tomography scan demonstrated decreased inflammation and shrinkage of the excluded abdominal aortic aneurysm.
authors.affiliation: Division of Vascular Surgery, The Ottawa Hospital, University of Ottawa, Civic Campus A-280, 1053 Carling Avenue, Ottawa, Ontario K1Y 4E9, Canada. pjetty@ottawahospital.on.ca
authors.forename: P
authors.initials: P
authors.lastname: Jetty
authors.forename: G G
authors.initials: GG
authors.lastname: Barber
mesh_terms: D058186:Acute Kidney Injury / Q000000981:diagnostic imaging / Q000209:etiology / Q000378:metabolism; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D017544:Aortic Aneurysm, Abdominal / Q000601:surgery*; D001025:Aortitis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology*; D019917:Blood Vessel Prosthesis Implantation; D002097:C-Reactive Protein / Q000378:metabolism; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D008297:Male; D011183:Postoperative Complications / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology*; D011241:Prednisone / Q000627:therapeutic use; D015607:Stents; D013629:Tamoxifen; D014057:Tomography, X-Ray Computed; D014517:Ureteral Obstruction / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology*; D014656:Vascular Surgical Procedures
chemical_list: D000893:Anti-Inflammatory Agents; D016588:Anticarcinogenic Agents; D018836:Inflammation Mediators; D013629:Tamoxifen; D002097:C-Reactive Protein; D011241:Prednisone